Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at Angiogenesis, Exudation, and Degeneration 2025.
Jennifer K. Sun, MD, MPH, said that in previous studies from the DRCR Retina Network, older patients with DME achieved less improvement in visual acuity.
“In our most recent Protocol AC, older age was associated with an increased risk of meeting the protocol-defined criteria for suboptimal treatment response, and older patients were therefore more likely to be switched from bevacizumab to aflibercept for treating DME,”